ERBB2 and breast cancer: Currently, adjuvant therapy indications in early HR+/HER2- breast cancer are mainly based on the individual prognostic profile as determined by clinical-pathological factors (tumor size, nodal status, grade, age), prognostic genomic signatures (e.g., RS) or protein markers such as uPA/PAI-1 [20,21].